{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T02:44:47Z","timestamp":1785465887564,"version":"3.56.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T00:00:00Z","timestamp":1726617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T00:00:00Z","timestamp":1726617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA"},{"DOI":"10.13039\/100012781","name":"MSD K.K., Tokyo, Japan","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012781","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s10147-024-02627-8","type":"journal-article","created":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T16:02:30Z","timestamp":1726675350000},"page":"1977-1983","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Pembrolizumab in Japanese patients with primary mediastinal large B-cell lymphoma: results from the KEYNOTE-A33 study"],"prefix":"10.1007","volume":"29","clinical-trial-number":[{"clinical-trial-number":"nct04317066","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5815-4585","authenticated-orcid":false,"given":"Koji","family":"Kato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sosuke","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Wakana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Izutsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,18]]},"reference":[{"key":"2627_CR1","doi-asserted-by":"publisher","first-page":"204062072110489","DOI":"10.1177\/20406207211048959","volume":"12","author":"B Fakhri","year":"2021","unstructured":"Fakhri B, Ai W (2021) Current and emerging treatment options in primary mediastinal B-cell lymphoma. Ther Adv Hematol 12:20406207211048960. https:\/\/doi.org\/10.1177\/20406207211048959","journal-title":"Ther Adv Hematol"},{"key":"2627_CR2","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1080\/10428190802108870","volume":"49","author":"J Kuruvilla","year":"2008","unstructured":"Kuruvilla J, Pintilie M, Tsang R et al (2008) Salvage chemotherapy and autologous stem cell transplantation are inferior for relapsed or refractory primary mediastinal large B-cell lymphoma compared with diffuse large B-cell lymphoma. Leuk Lymphoma 49:1329\u20131336. https:\/\/doi.org\/10.1080\/10428190802108870","journal-title":"Leuk Lymphoma"},{"key":"2627_CR3","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1016\/j.bbmt.2018.06.009","volume":"24","author":"S Vardhana","year":"2018","unstructured":"Vardhana S, Hamlin PA, Yang J et al (2018) Outcomes of relapsed and refractory primary mediastinal (thymic) large B cell lymphoma treated with second-line therapy and intent to transplant. Biol Blood Marrow Transplant 24:2133\u20132138. https:\/\/doi.org\/10.1016\/j.bbmt.2018.06.009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2627_CR4","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s12185-019-02681-3","volume":"110","author":"K Ohmachi","year":"2019","unstructured":"Ohmachi K (2019) JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma-5-diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS). Int J Hematol 110(2):131\u2013146. https:\/\/doi.org\/10.1007\/s12185-019-02681-3","journal-title":"Int J Hematol"},{"key":"2627_CR5","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1182\/blood.2020008376","volume":"140","author":"KJ Savage","year":"2022","unstructured":"Savage KJ (2022) Primary mediastinal large B-cell lymphoma. Blood 140:955\u2013970. https:\/\/doi.org\/10.1182\/blood.2020008376","journal-title":"Blood"},{"key":"2627_CR6","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1200\/JCO.19.01389","volume":"37","author":"P Armand","year":"2019","unstructured":"Armand P, Rodig S, Melnichenko V et al (2019) Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma. J Clin Oncol 37:3291\u20133299. https:\/\/doi.org\/10.1200\/JCO.19.01389","journal-title":"J Clin Oncol"},{"key":"2627_CR7","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1182\/blood-2016-12-758383","volume":"130","author":"PL Zinzani","year":"2017","unstructured":"Zinzani PL, Ribrag V, Moskowitz CH et al (2017) Safety and tolerability of pembrolizumab in patients with relapsed\/refractory primary mediastinal large B-cell lymphoma. Blood 130:267\u2013270. https:\/\/doi.org\/10.1182\/blood-2016-12-758383","journal-title":"Blood"},{"key":"2627_CR8","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1182\/blood.2022019340","volume":"142","author":"PLL Zinzani","year":"2023","unstructured":"Zinzani PLL, Thieblemont C, Melnichenko V et al (2023) Pembrolizumab in relapsed or refractory primary mediastinal large B-Cell lymphoma: final analysis of KEYNOTE-170. Blood 142:141\u2013145. https:\/\/doi.org\/10.1182\/blood.2022019340","journal-title":"Blood"},{"key":"2627_CR9","unstructured":"Ministry of Health Labour and Welfare of Japan. Overview of Orphan Drug\/Medical Device Designation System. Available via https:\/\/www.mhlw.go.jp\/english\/"},{"key":"2627_CR10","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","year":"2008","unstructured":"Swerdlow SH, Campo E, Harris NL et al (eds) (2008) WHO classification of tumours of haematopoietic and lymphoid tissues. WHO Press, Geneva"},{"key":"2627_CR11","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579\u2013586. https:\/\/doi.org\/10.1200\/JCO.2006.09.2403","journal-title":"J Clin Oncol"},{"key":"2627_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.113530","volume":"199","author":"JR Brahmer","year":"2024","unstructured":"Brahmer JR, Long GV, Hamid O et al (2024) Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients. Eur J Cancer 199:113530. https:\/\/doi.org\/10.1016\/j.ejca.2024.113530","journal-title":"Eur J Cancer"},{"key":"2627_CR13","doi-asserted-by":"publisher","first-page":"204062071984159","DOI":"10.1177\/2040620719841591","volume":"10","author":"S Tomassetti","year":"2019","unstructured":"Tomassetti S, Chen R, Dandapani S (2019) The role of pembrolizumab in relapsed\/refractory primary mediastinal large B-cell lymphoma. Ther Adv Hematol 10:2040620719841591. https:\/\/doi.org\/10.1177\/2040620719841591","journal-title":"Ther Adv Hematol"},{"key":"2627_CR14","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1182\/blood-2017-01-764258","volume":"129","author":"PL Zinzani","year":"2017","unstructured":"Zinzani PL, Pellegrini C, Chiappella A et al (2017) Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial. Blood 129:2328\u20132330. https:\/\/doi.org\/10.1182\/blood-2017-01-764258","journal-title":"Blood"},{"key":"2627_CR15","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1182\/blood-2014-09-598763","volume":"125","author":"ED Jacobsen","year":"2015","unstructured":"Jacobsen ED, Sharman JP, Oki Y et al (2015) Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed\/refractory DLBCL with variable CD30 expression. Blood 125:1394\u20131402","journal-title":"Blood"},{"key":"2627_CR16","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.1200\/JCO.19.01492","volume":"37","author":"PL Zinzani","year":"2019","unstructured":"Zinzani PL, Santoro A, Gritti G et al (2019) Nivolumab combined with brentuximab vedotin for relapsed\/refractory primary mediastinal large B-cell lymphoma: efficacy and safety from the phase II CheckMate 436 study. J Clin Oncol 37:3081\u20133089. https:\/\/doi.org\/10.1200\/JCO.19.01492","journal-title":"J Clin Oncol"},{"key":"2627_CR17","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson JS, Palomba ML, Gordon LI et al (2020) Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 396:839\u2013852. https:\/\/doi.org\/10.1016\/S0140-6736(20)31366-0","journal-title":"Lancet"},{"key":"2627_CR18","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL et al (2017) Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 377:2531\u20132544. https:\/\/doi.org\/10.1056\/NEJMoa1707447","journal-title":"N Engl J Med"},{"key":"2627_CR19","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s40290-022-00428-w","volume":"36","author":"A Gajra","year":"2022","unstructured":"Gajra A, Zalenski A, Sannareddy A et al (2022) Barriers to chimeric antigen receptor T-cell (CAR-T) therapies in clinical practice. Pharmaceut Med 36:163\u2013171. https:\/\/doi.org\/10.1007\/s40290-022-00428-w","journal-title":"Pharmaceut Med"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-024-02627-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-024-02627-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-024-02627-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T07:58:00Z","timestamp":1732607880000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-024-02627-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,18]]},"references-count":19,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["2627"],"URL":"https:\/\/doi.org\/10.1007\/s10147-024-02627-8","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,18]]},"assertion":[{"value":"15 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Koji Kato reports honoraria from Bristol Myers Squibb, Celgene, Dainippon-Sumitomo, Janssen, Kyowa Kirin, MSD, Mundi, and Ono; consulting or advisory roles with AbbVie, AstraZeneca, Celgene, Chugai Pharmaceutical, Daiichi Sankyo, Eisai, Janssen, and Novartis; and research funding from AbbVie, Bristol Myers Squibb, Celgene, Chugai, Daiichi Sankyo, Eisai, Janssen, Kyowa Kirin, MSD, Novartis, and Ono. Sosuke Nakamura reports employment at MSD K.K., Tokyo, Japan. Akira Wakana reports employment at MSD K.K., Tokyo, Japan, and stock ownership in Merck & Co., Inc., Rahway, NJ, USA. Yasuhiro Koh reports employment at MSD K.K., Tokyo, Japan, and stock ownership in Merck & Co., Inc., Rahway, NJ, USA. Koji Izutsu reports research grants from AstraZeneca, AbbVie, Incyte, Bristol Myers Squibb, Novartis, Janssen, Chugai, BeiGene, and Genmab. This study was designed under the responsibility of, and was supported by, Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, and MSD.K.K., Tokyo, Japan, in conjunction with the steering committee. Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, and MSD.K.K., Tokyo, collected and analyzed the data and contributed to the interpretation of the study. All authors had full access to all of the data in the study and had final responsibility for the decision to submit for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval of the research protocol by an Institutional Review Board: The study protocol and all amendments were approved by the appropriate institutional review boards and ethics review committees at each center. The study was conducted in accordance with the protocol, Good Clinical Practice guidelines, and the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All patients provided written informed consent before enrollment.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}